UNSPSC 51151673: Cimetropium bromide

This classification denotes an anticholinergic agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 0C7M5WE60Q. European Medicines Agency schedules Cimetropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06280MIG. Cimetropium bromide generally arises in the molecular formula C21H28BRNO4. The term CIMETROPIUM BROMIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 38, no. 6, 1984, list 24.)

UNSPSC 51151673 Cimetropium bromide is a Commodity code that shows minimal relevant recent procurement activity under state and local contracting. The code nominally describes a specific pharmaceutical compound (cimetropium bromide, an anticholinergic agent), but the recent opportunities posted under this code do not reflect purchases of that substance. Instead, the tagged solicitations cover naloxone (an opioid antagonist) and direct-to-manufacturer prescription program administration — products and services outside the scope of the cimetropium bromide commodity itself. This mismatch suggests either classification error in the tagging system or that state and local procurement offices are using this code as a catch-all for pharmaceutical-adjacent procurement rather than for the specific active ingredient the code nominally describes.

The two recent opportunities span different issuing bodies and procurement mechanisms: Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries, while the Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program. Geographic activity is concentrated in Florida and Texas, but the small sample size and the substantive mismatch between the code's nominal scope and the actual work being solicited make this code unsuitable for targeting state and local pharmaceutical procurement without further clarification of tagging practices at the issuing jurisdictions. Businesses pursuing pharmaceutical sales to state and local health agencies should verify the correct UNSPSC codes used by specific jurisdictions rather than rely on this classification.